Clarametyx

Overview

Clarametyx is targeting chronic lung infections caused by the bacterial pathogen Pseudomonas aeruginosa. This pathogen is responsible for many severe infections due to its ability to produce biofilms that protect it from antimicrobials. Clarametyx has developed an antibody that is able to rapidly destroy these biofilms, allowing antibiotics to clear out the infection. The company is also developing a vaccine to help prevent biofilms from forming in the first place.